Cantor Fitzgerald resumed coverage on Gilead Sciences with a new price target
$GILD
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Cantor Fitzgerald resumed coverage of Gilead Sciences with a rating of Overweight and set a new price target of $125.00